We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $44.43 in the latest trading session, marking a +2.87% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.03%. Elsewhere, the Dow saw a downswing of 0.11%, while the tech-heavy Nasdaq appreciated by 0.13%.
The company's shares have seen an increase of 10.04% over the last month, surpassing the Medical sector's gain of 1.25% and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. The company is predicted to post an EPS of -$1.54, indicating a 3.36% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $5.89 million, indicating a 1032.88% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.54 per share and a revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.68% decrease. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $44.43 in the latest trading session, marking a +2.87% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.03%. Elsewhere, the Dow saw a downswing of 0.11%, while the tech-heavy Nasdaq appreciated by 0.13%.
The company's shares have seen an increase of 10.04% over the last month, surpassing the Medical sector's gain of 1.25% and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. The company is predicted to post an EPS of -$1.54, indicating a 3.36% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $5.89 million, indicating a 1032.88% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.54 per share and a revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.68% decrease. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.